218 related articles for article (PubMed ID: 25917051)
21. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
23. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
[TBL] [Abstract][Full Text] [Related]
24. Is there a role for tumor necrosis factor-alpha (TNF-alpha) in oral lichen planus?
Sugermann PB; Savage NW; Seymour GJ; Walsh LJ
J Oral Pathol Med; 1996 May; 25(5):219-24. PubMed ID: 8835818
[TBL] [Abstract][Full Text] [Related]
25. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases.
Denadai R; Teixeira FV; Steinwurz F; Romiti R; Saad-Hossne R
J Crohns Colitis; 2013 Aug; 7(7):517-24. PubMed ID: 22960136
[TBL] [Abstract][Full Text] [Related]
26. Infliximab-induced psoriasis during therapy for Crohn's disease.
Steinwurz F; Denadai R; Saad-Hossne R; Queiroz ML; Teixeira FV; Romiti R
J Crohns Colitis; 2012 Jun; 6(5):610-6. PubMed ID: 22398095
[TBL] [Abstract][Full Text] [Related]
27. Psoriasis induced by anti-tumour necrosis factor therapy in patients with inflammatory bowel disease.
Salgueiro P; Lago P; Pedroto I
J Crohns Colitis; 2013 Sep; 7(8):e325-6. PubMed ID: 23352103
[No Abstract] [Full Text] [Related]
28. Biologics, an alternative therapeutic approach for oral lichen planus.
Zhang J; Zhou G; Du GF; Xu XY; Zhou HM
J Oral Pathol Med; 2011 Aug; 40(7):521-4. PubMed ID: 21463368
[TBL] [Abstract][Full Text] [Related]
29. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
30. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?
Gisbert JP; Chaparro M
Scand J Gastroenterol; 2015 Apr; 50(4):379-86. PubMed ID: 25636030
[TBL] [Abstract][Full Text] [Related]
31. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
32. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up.
Lehtola E; Haapamäki J; Färkkilä MA
Scand J Gastroenterol; 2016 Dec; 51(12):1476-1481. PubMed ID: 27686143
[TBL] [Abstract][Full Text] [Related]
33. Expression of TNF-alpha in oral lichen planus treated with fluocinolone acetonide 0.1%.
Thongprasom K; Dhanuthai K; Sarideechaigul W; Chaiyarit P; Chaimusig M
J Oral Pathol Med; 2006 Mar; 35(3):161-6. PubMed ID: 16454812
[TBL] [Abstract][Full Text] [Related]
34. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
35. Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis.
Wang F; Lin X; Zhao Q; Li J
Eur J Clin Pharmacol; 2015 Aug; 71(8):911-9. PubMed ID: 26022220
[TBL] [Abstract][Full Text] [Related]
36. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
[TBL] [Abstract][Full Text] [Related]
38. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the association between TNF-α-1031 T/C polymorphism with oral lichen planus disease.
Marabi MH; Mozaffari HR; Ghasemi H; Hatami M; Yari K
BMC Oral Health; 2024 Feb; 24(1):189. PubMed ID: 38317095
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus.
Carrozzo M; Uboldi de Capei M; Dametto E; Fasano ME; Arduino P; Broccoletti R; Vezza D; Rendine S; Curtoni ES; Gandolfo S
J Invest Dermatol; 2004 Jan; 122(1):87-94. PubMed ID: 14962095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
